StoxGland Pharma Ltd.
NSE: GLAND · Healthcare
Ask the data
Instant answers about Gland Pharma Ltd. — computed from its filings, no language modelPrice & valuation
split & bonus adjusted · pick a metric and rangeAnnual performance
annual · ₹ crore · line = operating margin| FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|
| Revenue | 3,463 | 4,401 | 3,625 | 5,665 | 5,616 | 6,431 |
| EBITDA | 1,302 | 1,510 | 1,025 | 1,333 | 1,269 | 1,630 |
| Operating margin | 37.6% | 34.3% | 28.3% | 23.5% | 22.6% | 25.3% |
| Interest | 3 | 5 | 7 | 26 | 42 | 33 |
| Depreciation | 99 | 110 | 147 | 345 | 378 | 424 |
| Profit before tax | 1,335 | 1,619 | 1,055 | 1,133 | 1,063 | 1,465 |
| Tax | 338 | 407 | 274 | 360 | 364 | 437 |
| Net profit | 997 | 1,212 | 781 | 772 | 699 | 1,027 |
| EPS ₹ | 63.07 | 73.81 | 47.44 | 46.90 | 42.40 | 62.35 |
| Operating cash flow | — | 791 | 364 | 997 | 915 | 1,031 |
| Capex | — | 522 | 223 | 398 | 394 | 494 |
| Dividend paid | — | 0 | 0 | 0 | 329 | 297 |
| Total assets | 6,496 | 7,834 | 8,778 | 10,661 | 11,225 | 12,511 |
| Equity | 5,903 | 7,158 | 7,959 | 8,724 | 9,151 | 10,358 |
Quarterly performance
last 21 quarters · ₹ crore| MAR '21 | JUN '21 | SEP '21 | DEC '21 | MAR '22 | SEP '22 | DEC '22 | MAR '23 | JUN '23 | SEP '23 | DEC '23 | MAR '24 | JUN '24 | SEP '24 | DEC '24 | MAR '25 | JUN '25 | SEP '25 | DEC '25 | MAR '26 | JUN '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 888 | 1,154 | 1,080 | 1,063 | 1,103 | 1,044 | 938 | 785 | 1,209 | 1,373 | 1,545 | 1,537 | 1,402 | 1,406 | 1,384 | 1,425 | 1,506 | 1,487 | 1,695 | 1,743 | 1,800 |
| Operating profit | 328 | 436 | 377 | 349 | 348 | 297 | 290 | 168 | 294 | 324 | 356 | 359 | 264 | 297 | 360 | 348 | 368 | 314 | 435 | 513 | 489 |
| Operating margin | 36.9% | 37.8% | 34.9% | 32.8% | 31.6% | 28.4% | 30.9% | 21.5% | 24.3% | 23.6% | 23.1% | 23.3% | 18.9% | 21.1% | 26.0% | 24.4% | 24.4% | 21.1% | 25.7% | 29.4% | 27.2% |
| Other income | 47 | 62 | 51 | 46 | 65 | 66 | 62 | 39 | 38 | 53 | 37 | 42 | 51 | 60 | 58 | 44 | 58 | 84 | 63 | 111 | 61 |
| Interest | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 2 | 5 | 6 | 5 | 10 | 6 | 6 | 23 | 7 | 12 | 8 | 4 | 10 | 4 |
| Depreciation | 25 | 25 | 26 | 28 | 31 | 37 | 38 | 38 | 65 | 81 | 105 | 93 | 92 | 94 | 96 | 96 | 101 | 106 | 108 | 109 | 111 |
| Profit before tax | 349 | 472 | 401 | 366 | 380 | 324 | 311 | 111 | 261 | 290 | 283 | 298 | 218 | 257 | 299 | 288 | 313 | 284 | 362 | 506 | 435 |
| Tax | 89 | 121 | 99 | 93 | 95 | 83 | 79 | 32 | 67 | 96 | 91 | 106 | 74 | 93 | 95 | 102 | 97 | 100 | 101 | 139 | 118 |
| Net profit | 260 | 351 | 302 | 273 | 286 | 241 | 232 | 79 | 194 | 194 | 192 | 192 | 144 | 164 | 205 | 187 | 215 | 184 | 261 | 367 | 317 |
| EPS ₹ | 15.93 | 21.41 | 18.37 | 16.62 | 17.40 | 14.65 | 14.08 | 4.78 | 11.79 | 11.78 | 11.65 | 11.68 | 8.73 | 9.93 | 12.42 | 11.32 | 13.08 | 11.15 | 15.87 | 22.26 | 19.23 |
| Revenue YoY | — | — | — | — | 24.2% | -3.3% | -11.8% | -28.8% | — | 31.5% | 64.7% | 95.9% | 16.0% | 2.4% | -10.4% | -7.3% | 7.4% | 5.8% | 22.5% | 22.3% | 19.6% |
| Profit YoY | — | — | — | — | 9.8% | -20.1% | -15.0% | -72.5% | — | -19.5% | -17.3% | 144.6% | -25.9% | -15.7% | 6.7% | -3.1% | 49.9% | 12.3% | 27.7% | 96.6% | 47.1% |
Earlier results (standalone, Dec '20 – Dec '20)
₹ crore · from BSE, before the NSE XBRL filings beginGland Pharma Ltd. reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.
Quarters
| DEC '20† | |
|---|---|
| Revenue | 859 |
| Operating profit | 264 |
| Operating margin | 30.7% |
| Other income | 35 |
| Interest | 1 |
| Depreciation | 25 |
| Profit before tax | 273 |
| Tax | 69 |
| Net profit | 204 |
| EPS ₹ | 12.83 |
Returns & margins
trailing-twelve-month, per quarter| DEC '21 | MAR '22 | JUN '23 | SEP '23 | DEC '23 | MAR '24 | JUN '24 | SEP '24 | DEC '24 | MAR '25 | JUN '25 | SEP '25 | DEC '25 | MAR '26 | JUN '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 20.1% | 16.9% | 9.4% | 8.4% | 7.9% | 8.9% | 8.3% | 7.9% | 8.0% | 7.6% | 8.4% | 8.3% | 8.9% | 9.9% | 10.9% |
| ROCE | 26.9% | 22.7% | 12.8% | 11.5% | 11.2% | 12.8% | 12.3% | 11.9% | 12.3% | 11.7% | 12.8% | 12.6% | 13.0% | 14.1% | 15.2% |
| Net margin | 28.3% | 27.5% | 18.8% | 16.2% | 13.4% | 13.6% | 12.3% | 11.7% | 12.3% | 12.4% | 13.5% | 13.6% | 13.9% | 16.0% | 16.8% |
| EBITDA margin | 35.6% | 34.3% | 26.4% | 25.0% | 23.3% | 23.5% | 22.3% | 21.7% | 22.3% | 22.6% | 24.0% | 23.9% | 24.0% | 25.3% | 26.0% |
| Debt / equity | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 |
| Interest coverage | 377.07 | 310.47 | 88.90 | 62.63 | 52.24 | 44.21 | 41.49 | 40.17 | 25.10 | 26.30 | 25.17 | 24.88 | 41.62 | 45.01 | 61.71 |
| Asset turnover | 0.64 | 0.56 | 0.45 | 0.42 | 0.48 | 0.53 | 0.55 | 0.54 | 0.53 | 0.50 | 0.51 | 0.49 | 0.52 | 0.51 | 0.54 |
Balance sheet
equity vs borrowings over time · ₹ crore| MAR '20‡ | MAR '21‡ | MAR '22‡ | SEP '22 | MAR '23 | SEP '23 | MAR '24 | SEP '24 | MAR '25 | SEP '25 | MAR '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share capital | 15 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Other equity / reserves | 3,631 | 5,887 | 7,141 | 7,635 | 7,942 | 8,290 | 8,707 | 8,772 | 9,134 | 9,546 | 10,341 |
| Total equity | 3,646 | 5,903 | 7,158 | 7,651 | 7,959 | 8,307 | 8,724 | 8,788 | 9,151 | 9,563 | 10,358 |
| Borrowings | 4 | 4 | 4 | 4 | 4 | 313 | 320 | 279 | 269 | 256 | 243 |
| Current liabilities | 359 | 513 | 582 | 870 | 729 | 1,536 | 1,398 | 1,539 | 1,565 | 1,706 | 1,608 |
| Non-current liabilities | 81 | 80 | 94 | 100 | 90 | 450 | 539 | 540 | 509 | 531 | 544 |
| Total assets | 4,086 | 6,496 | 7,834 | 8,621 | 8,778 | 10,293 | 10,661 | 10,867 | 11,225 | 11,800 | 12,511 |
| Property, plant & equipment | 967 | 953 | 1,499 | 1,553 | 1,558 | 3,050 | 3,541 | 3,610 | 3,751 | 3,965 | 4,052 |
| Capital work-in-progress | 188 | 338 | 181 | 125 | 177 | 320 | 238 | 277 | 151 | 209 | 342 |
| Investments | — | 0 | 155 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventories | 756 | 1,275 | 1,186 | 1,560 | 1,945 | 2,084 | 1,655 | 1,577 | 1,685 | 1,814 | 1,744 |
| Receivables | 602 | 671 | 1,199 | 1,201 | 871 | 1,373 | 1,559 | 1,490 | 1,517 | 1,565 | 1,891 |
| Cash & equivalents | 170 | 492 | 319 | 534 | 1,909 | 481 | 357 | 2,820 | 2,556 | 2,704 | 3,359 |
Cash flow
annual · ₹ crore · line = free cash flow| FY20‡ | FY21‡ | FY22 | FY23 | FY24 | FY25 | FY26 | |
|---|---|---|---|---|---|---|---|
| Cash from operations | 701 | 605 | 791 | 364 | 997 | 915 | 1,031 |
| Cash from investing | -766 | -1,524 | -1,003 | 1,208 | -1,757 | 1,705 | 138 |
| Cash from financing | -7 | 1,238 | 35 | 15 | -799 | -433 | -417 |
| Capex | 195 | 229 | 522 | 223 | 398 | 394 | 494 |
| Free cash flow | 506 | 376 | 269 | 141 | 599 | 521 | 537 |
| Dividends paid | — | — | 0 | 0 | 0 | 329 | 297 |
Where the assets sit
Mar '26 · ₹ crorePeer comparison
largest in Healthcare · this company in bold| Company | Market cap ₹cr | Price | P/E | P/B | ROE |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,46,270 | 1,860.00 | 40.7 | 5.00 | 12.3% |
| Divi's Laboratories Ltd. | 2,73,493 | 10,320.50 | 93.5 | 16.32 | 17.5% |
| Torrent Pharmaceuticals Ltd. | 1,80,671 | 4,750.00 | 85.1 | 9.83 | 11.6% |
| Laurus Labs Ltd. | 1,26,430 | 2,340.00 | 94.4 | 20.86 | 22.1% |
| Apollo Hospitals Enterprise Ltd. | 1,21,453 | 8,446.00 | 54.2 | 11.45 | 21.1% |
| Zydus Lifesciences Ltd. | 1,19,550 | 1,197.90 | 28.6 | 4.30 | 15.0% |
| Dr. Reddy's Laboratories Ltd. | 1,14,646 | 1,373.00 | 40.9 | 2.95 | 7.2% |
| Cipla Ltd. | 1,13,988 | 1,411.00 | 39.3 | 3.22 | 8.2% |
| Mankind Pharma Ltd. | 1,04,902 | 2,540.00 | 46.7 | 5.97 | 12.8% |
| Aurobindo Pharma Ltd. | 1,03,572 | 1,800.00 | 26.0 | 2.63 | 10.1% |
| Gland Pharma Ltd. | 52,281 | 3,169.30 | 46.3 | 5.05 | 10.9% |
StoxGud checklist: Bullish setup · 9/10
- Price above 50-day average
- Price above 200-day average
- 50-day average above 200-day (uptrend)
- RSI in healthy 40–70 zone
- Positive 1-year return
- Return on equity above 15%
- Debt to equity below 1
- Revenue growing year on year
- Net profit margin above 10%
- P/E below industry median
A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.
Returns & technicals
Compare Gland Pharma Ltd. with
FAQs
What is the share price of Gland Pharma Ltd.?
Gland Pharma Ltd. (GLAND) closed at ₹3,169.30 on NSE on 06 Nov 2026.
What is the market cap of Gland Pharma Ltd.?
₹52,281 crore at the latest close.
What is the P/E ratio of Gland Pharma Ltd.?
46.3, on trailing-twelve-month earnings from its filings.
How fast is Gland Pharma Ltd. growing?
Gland Pharma Ltd.: revenue has compounded at 21.1% a year over three years; net profit at 9.6% a year. Latest-quarter revenue is up 19.6% year on year, profit up 47.1%.
How profitable is Gland Pharma Ltd.?
On a trailing-twelve-month basis return on equity is 10.9%, return on capital employed 15.2%, operating margin 26.0%, net margin 16.8%.
How much debt does Gland Pharma Ltd. have?
Gland Pharma Ltd. is debt-free: debt to equity is 0.02 with borrowings of ₹243 cr against cash of ₹3,359 cr (balance sheet of 2026-03-31). Operating profit covers interest 61.7 times.
Financials parsed from Gland Pharma Ltd.'s own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from MAR '21, annual from FY21, balance sheet from Mar '20. * = derived (full year or half year minus earlier quarters). ‡ = balance sheet / cash flow read from the company's published annual report (same basis), for years before the NSE filings carry them; each one checked to add up. Information only, not investment advice.